Teladoc Shares Slip 2.6% to $4.85 as Monthly Drop Hits 31%
Teladoc Health shares declined 2.61% to $4.85 in the latest session, underperforming the S&P 500 and falling 31.31% over the past month versus a 1.02% sector drop. Analysts forecast a Q4 EPS of -$0.19 on $633.9 million revenue, with full-year EPS of -$1.19 on $2.52 billion revenue.
1. Session Performance
Teladoc closed at $4.85, down 2.61% from the prior day, trailing the S&P 500’s 0.33% loss, the Nasdaq’s 0.59% decline and the Dow’s 0.1% gain.
2. Monthly Underperformance
Over the past month, shares have plunged 31.31%, far exceeding the Medical sector’s 1.02% drop and the flat performance of the S&P 500.
3. Earnings Forecasts
For the quarter ending February 25, analysts expect EPS of -$0.19 and revenue of $633.91 million, a 1.03% year-over-year revenue decline; full-year projections call for EPS of -$1.19 and $2.52 billion in sales.
4. Analyst Consensus
Consensus EPS estimates have remained unchanged in the last 30 days and analysts maintain a Hold rating; the Medical Services industry ranks in the bottom 43% by average analyst ratings.